Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuropsychiatric & Neurodegenerative Disorder Development.
Key Mutations and Clinical Significance
Based on UniProt entry Q05586, several clinically relevant mutations have been identified in the GRIN1 gene. The NDHMSR variant alters glutamate-gated calcium ion channel activity and is associated with increased inhibition (VAR_079984). An additional NDHMSR variant of uncertain significance is cataloged as dbSNP rs869312865 (VAR_079985). A separate mutation found in a patient with schizophrenia also carries uncertain significance (VAR_079986). These mutations underscore the importance of functional assays using native-like ion channel conformations to evaluate variant impact on channel gating and pharmacology.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NMDAR1/GRIN1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GRIN1/NMDAR1 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/µg. HEK293 Expressed (Native Glycosylation). Sequence Verified. |
View GRIN1 Products |
| Gene Delivery | GRIN1 Full-Length Lentivirus Particles For stable cell line construction preserving native ion channel conformation. Calcium flux compatible. |
View GRIN1 Products |
| Benchmark Ab | Anti-GRIN1 (Reference Clone) Recombinant positive control for binding assays. Sequence Verified. |
View GRIN1 Products |
| Validator | GRIN1 siRNA Set (3 target-specific + 1 control) For knockdown verification and assay specificity confirmation. |
View GRIN1 Products |
| Related Target: GRIN2A | GluN2A Subunit (Regulatory) Determines Mg2+ sensitivity; essential for di-heteromeric receptor assays and subtype selectivity testing. |
View GRIN2A Products |
| Related Target: GRIN2B | GluN2B Subunit (Forebrain Predominant) Critical for cognitive function assays; target for avoiding psychotomimetic side effects. |
View GRIN2B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native Ion Channel Conformation Preservation | Full-length GRIN1 Lentivirus for stable cell lines; HEK293 expression system maintains native glycosylation patterns required for proper channel assembly. |
| Subtype Selectivity (GluN2A vs GluN2B) | Matched GRIN2A and GRIN2B protein panel available with identical expression systems (>95% purity) for consistent binding kinetics. |
| Use-Dependent vs Closed-Channel Binding | Functional cell lines (Ca²⁺ flux validated) available for mechanism-of-action studies; preserves physiological activation states. |
| Cross-Species Translation (Cyno/Rat) | Ortholog protein variants (Human/Cynomolgus/Rat) with sequence-verified ECD homology for preclinical safety bridging. |
| Assay Specificity Controls | Validated siRNA sets and reference-grade antibodies included for target engagement confirmation. |
Live NMDAR1/GRIN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (NMDAR1)
- ➤ Alternative Search (GRIN1)
- ➤ Latest Resistance & Selectivity Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for NMDAR1-targeting therapeutics is pivoting from broad ion channel blockade toward sophisticated allosteric modulation. As first-generation NMDA antagonists (e.g., esketamine) establish efficacy in treatment-resistant depression, the next wave of R&D focuses on subtype-selective modulation through GluN2A/GluN2B selectivity to dissociate cognitive benefits from psychotomimetic liabilities. Major development efforts now concentrate on use-dependent blockers and positive allosteric modulators (PAMs) for Alzheimer's cognitive decline and schizophrenia negative symptoms. The primary focus remains on Schizophrenia, Major Depressive Disorder (MDD), Alzheimer's disease, and neuroprotection in stroke/TBI.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Negative Allosteric Modulators (NAMs) | AstraZeneca, Relmada Therapeutics | Neuroprotection (Stroke, TBI); Depression | Use-Dependent Blocking Assay (Requires functional lentivirus-stable cells with physiological Ca²⁺ responses) |
| Positive Allosteric Modulators (PAMs) | Cerecor/Avalo, Novartis, Boehringer Ingelheim, Lundbeck | Alzheimer's Cognition, Schizophrenia | Glycine Site Potentiation Assay (Need high-purity GRIN1 ECD with native glycosylation) |
| GluN2B-Selective Antagonists | Allergan (legacy), Biogen, Cerevel (AbbVie) | Refractory Depression, Parkinson's, Epilepsy | Heterodimer Validation (GRIN1+GRIN2B co-expression required for accurate affinity) |
| Subunit-Selective Small Mols | Johnson & Johnson (GluN2A PAMs) | Intellectual Disability, ASD | Di-heteromeric vs Tri-heteromeric Selectivity Panel (GRIN2A/2B/2D combination testing) |
| Biologics / Peptides | Emerging Biotechs | Ischemic Stroke | Internalization/Binding Assay (Need high-purity Sequence Verified ECD-Fc) |